Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $11.0 million.

  • Xeris Biopharma Holdings' Cost of Revenue fell 19.11% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 17.68%. This contributed to the annual value of $36.8 million for FY2024, which is 28.58% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Cost of Revenue stood at $11.0 million, which was down 7.58% from $11.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Cost of Revenue's 5-year high stood at $13.6 million during Q3 2024, with a 5-year trough of $1.8 million in Q1 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Cost of Revenue averaged around $8.8 million, with its median value being $8.2 million (2023).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Cost of Revenue spiked by 243.54% in 2022 and then decreased by 19.11% in 2025.
  • Xeris Biopharma Holdings' Cost of Revenue (Quarterly) stood at $4.9 million in 2021, then rose by 28.68% to $6.3 million in 2022, then grew by 20.33% to $7.6 million in 2023, then rose by 25.20% to $9.5 million in 2024, then fell by 19.11% to $11.0 million in 2025.
  • Its Cost of Revenue stands at $11.0 million for Q3 2025, versus $11.9 million for Q2 2025 and $8.7 million for Q1 2025.